Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.
Despite recognition of the malignant potential of human melanomas, the mechanisms responsible for the pathobiological characteristics contributing to tumor growth, vascular invasiveness, and distant organ metastasis remain undefined. Recent studies have shown that various human tumors express an inducible form of nitric oxide synthase (iNOS) and nitrotyrosine (NT), which suggests a mechanistic role of tumor-associated nitric oxide (NO) in tumorigenesis. We investigated iNOS and NT expression by immunohistochemistry in 20 human metastatic melanoma tissue specimens specifically with respect to iNOS-expressing cell types in the tumor area, pathological and clinical response to systemic therapy, potential role as a prognostic indicator, and NT formation. Our results showed that melanoma cells from 12 of 20 tumors express iNOS, yet the expression of this molecule in the tumor did not correlate with pathological or clinical response to therapy. More importantly, iNOS and NT expression by the melanoma cells strongly correlated with poor survival in patients with stage 3 disease (P < 0.001 and P = 0.020, respectively), suggesting a pathway whereby iNOS might contribute to enhanced tumor progression. In conclusion, our findings strongly suggest that iNOS expression has potential to be considered as a prognostic factor and NO as a critical mediator of an aggressive tumor phenotype in human metastatic melanomas.
Ekmekcioglu
S
S
Department of Molecular and Cellular Oncology, University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA.
Ellerhorst
J
J
Smid
C M
CM
Prieto
V G
VG
Munsell
M
M
Buzaid
A C
AC
Grimm
E A
EA
D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008545:Melanoma / Q000097:blood / Q000175:diagnosis* / Q000378:metabolism* / Q000401:mortality*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D019001:Nitric Oxide Synthase / Q000096:biosynthesis* / Q000097:blood; D052247:Nitric Oxide Synthase Type II; D011379:Prognosis; D013997:Time Factors; D016896:Treatment Outcome; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000096:biosynthesis* / Q000097:blood
C002744:3-nitrotyrosine; D014443:Tyrosine; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II